Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot could tame severe eczema in kids

NCT ID NCT04921345

Completed Disease control Sponsor: Galderma R&D Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called nemolizumab in 109 children aged 2 to 11 with moderate-to-severe eczema. The drug is given as a shot under the skin every 4 weeks for a year. Researchers measured how the drug moves through the body, its safety, and whether it improves eczema symptoms. The goal is to see if this treatment can help control this chronic skin condition in young children.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Nemolizumab (a drug given as a shot under the skin)
What this could lead to
If successful, this could provide a new treatment option for children with hard-to-control eczema, potentially reducing itching and skin inflammation.
What could go wrong
This is a small, early-phase trial (Phase 2) with no placebo group, so results are preliminary. Side effects or lack of clear benefit may limit future use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MODERATE-TO-SEVERE ATOPIC DERMATITIS

Contacts and locations

Locations

  • Galderma Investigational Site #5495

    Rzeszów, 35-055, Poland

  • Galderma Investigational Site #5531

    Szeged, 6720, Hungary

  • Galderma Investigational Site #5570

    Lodz, 90-265, Poland

  • Galderma Investigational Site #5896

    Esplugues de Llobregat, 0850, Spain

  • Galderma Investigational Site #6147

    Budapest, 1036, Hungary

  • Galderma Investigational Site #6218

    Hellerup, 2900, Denmark

  • Galderma Investigational Site #6237

    Ostrowiec Świętokrzyski, 27-400, Poland

  • Galderma Investigational Site #6261

    Wroclaw, 51-685, Poland

  • Galderma Investigational Site #6262

    Warsaw, 02-953, Poland

  • Galderma Investigational Site #78218-3128

    San Antonio, Texas, 78218-3128, United States

  • Galderma Investigational Site #8092

    Louisville, Kentucky, 40217-1444, United States

  • Galderma Investigational Site #8142

    Indianapolis, Indiana, 46250-2041, United States

  • Galderma Investigational Site #8155

    Troy, Michigan, 48084-5260, United States

  • Galderma Investigational Site #8206

    Norman, Oklahoma, 73069-6301, United States

  • Galderma Investigational Site #8242

    Brooklyn, New York, 11203-2012, United States

  • Galderma Investigational Site #8255

    Philadelphia, Pennsylvania, 19103-4708, United States

  • Galderma Investigational Site #8560

    West Bloomfield, Michigan, 48322, United States

  • Galderma Investigational Site #8636

    Fountain Valley, California, 92708-3701, United States

  • Galderma Investigational Site #9929

    Coral Gables, Florida, 92083-6031, United States

  • Galderma Investigational Site #9930

    Vista, California, 92083-6031, United States

  • Galderma Investigational Site #9931

    Beaumont, Texas, 77706-3061, United States

  • Galderma Investigational Site #9937

    San Diego, California, 92123-2746, United States

  • Galderma Investigational Site #9938

    New York, New York, 10032-3729, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.